BACK

M65® ELISA References

REFERENCES IN CHRONOLOGICAL ORDER

(Updated on 25 January 2012)

Year of publication:
» 2012
» 2011
» 2010
» 2009
» 2008
» 2007
» 2004 – 2006

Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Kevin Park B (2012)
Molecular forms of HMGB1 and Keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity
J Hepatol 2012, , [Epub ahead of print]
»Abstract

Koo JH, Lee MH, Kim SS, Kim DH, Kim IS, Lee KM, Yoo BM, Lee KJ, Kim JH, Cho SW, Cheong JY (2012)
Changes in serum histologic surrogate markers and procollagen III N-terminal peptide as independent predictors of HBeAg loss in patients with chronic hepatitis B during entecavir therapy.
Clin Biochem. 2012, 45(1-2), 31-6
»Abstract

Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C (2012)
A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients
Clin Drug Investig 2012, , [Epub ahead of print]
»Abstract

Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I (2011)
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Ann Oncol. 2011, , [Epub ahead of print]
»Abstract

Barut O, Vural P, Sirin S, Aydin S, Dizdar Y (2011)
The oxidant/antioxidant status and cell death mode in oral squamous cell carcinoma
Acta Odontol Scand. 2011, , [Epub ahead of print]
»Abstract

Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M. (2011)
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Cancer Chemother Pharmacol 2011, 68(2), 309-16
»Abstract

Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC (2011)
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis
Eur J Gastroenterol Hepatol. 2011, 23(5), 382-8
»Abstract

Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C. (2011)
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Neoplasia. 2011 Apr 2011, 13(4), 339-47
»Abstract

Dowman JK, Tomlinson JW, Newsome PN. (2011)
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Aliment Pharmacol Ther. 2011, 33(5), 525-40
»Abstract

Esaki Taito, Takashi Seto, Hiroshi Ariyama, Shuji Arita, Chinatsu Fujimoto, Koichiro Tsukasa, Takuro Kometani, Kaname Nosaki, Fumihiko Hirai, and Katsuro Yagawa (2011)
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors
Arch Drug Info 2011, 4(2), 23-31
»Abstract

Farnik H, Lange CM, Hofmann WP, Berger A, Allwinn R, Welker MW, Trojan J, Sarrazin C, Herrmann E, Zeuzem S, Kronenberger B (2011)
Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B.
J Clin Virol. 2011, 52(3), 204-9
»Abstract

Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. (2011)
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
J Clin Oncol. 2011, 29(7), 909-16
»Abstract

Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C. (2011)
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
Br J Cancer 2011, 104(4), 719-25
»Abstract

Herzer K, Kneiseler G, Bechmann LP, Post F, Schlattjan M, Sowa JP, Neumann T, Marggraf G, Erbel R, Gerken G, Canbay A, Jochum C. (2011)
Onset of heart failure determines the hepatic cell death pattern.
Ann Hepatol. 2011 Apr 2011, 10(2), 174-9
»Abstract

Janciauskiene S, Wallmark A, Piitulainen E, Köhnlein T, Welte T, Sveger T. (2011)
Performance of enhanced liver fibrosis plasma markers in asymptomatic individuals with ZZ α1-antitrypsin deficiency.
Eur J Gastroenterol Hepatol. 2011, 23(8), 716-20
»Abstract

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-Osthoff K, Bantel H (2011)
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.
Hepatology 2011, , [Epub ahead of print]
»Abstract

Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Brustel Y, Tran A, Gual P. (2011)
Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease.
PLoS One. 2011, 6(3), e17599.
»Abstract

Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H (2011)
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
Ann Oncol. 2011, 22(9), 2137-43
»Abstract

Miller MH, Ferguson MA, Dillon JF (2011)
Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease
Liver Int. 2011, 31(4), 461-73
»Abstract

Musso G, Gambino R, Cassader M, Pagano G (2011)
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
Ann Med. 2011, 43(8), 617-49
»Abstract

Olszewski-Hamilton U, Ausch C, Buxhofer-Ausch V, Hamilton G (2011)
Significance of Cytokeratin Fragment M65 and Cytokines IL6, IL8 and IL17A in Bone Marrow Aspirates of Colorectal Cancer Patients
British Journal of Medicine & Medical Research 2011, 1(4), 170-181
»Abstract

Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM (2011)
Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.
Br J Cancer 2011, 105(12), 1830-8
»Abstract

Richard J, Lingvay I. (2011)
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.
Expert Rev Cardiovasc Ther. 2011 Mar;9(3):321-8. 2011, 9(3), 321-8
»Abstract

Roth, Diana Lebherz-Eichingera, f, Hendrik Jan Ankersmitb, Stefan Hackerb, Hubert Hetza, f, Thomas Vukovichc, Andrea Pernec, Thomas Reiterd, Alexander Farre, Walter H. Hörld, Martin Haasd and Claus G. Krenn (2011)
Increased total cytokeratin-18 serum and urine levels in chronic kidney disease
Clinica Chimica Acta 2011, 412(9-10), 713-717

Snoeijs MG, van Bijnen A, Swennen E, Haenen GR, Roberts LJ 2nd, Christiaans MH, Peppelenbosch AG, Buurman WA, Ernest van Heurn LW (2011)
Tubular epithelial injury and inflammation after ischemia and reperfusion in human kidney transplantation
Ann Surg 2011, 253(3), 598-604
»Abstract

Yilmaz Y, (2011)
Cytokeratins in hepatitis
Clin Chim Acta 2011, 412(23-24), 2031-6
»Abstract

Bantel H, Simon HU. (2010)
DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria.
Cell Cycle. 2010, 9(14), 2710-1
»Abstract

Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, Canbay A. (2010)
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury.
J Hepatol. 2010, 53(4), 639-47
»Abstract

Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, Emons B, Jochum C, Feldkamp T, Gerken G, Canbay A. (2010)
Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis.
Liver Int. 2010, 30(6), 850-9
»Abstract

Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M. (2010)
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
Cancer Chemother Pharmacol 2010, , [Epub ahead of print]
»Abstract

Brandt D, Volkmann X, Anstätt M, Länger F, Manns MP, Schulze-Osthoff K, Bantel H. (2010)
Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas.
Eur J Cancer. 2010, 46(8), 1464-73
»Abstract

Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, Bon Homme M, McClain CJ. (2010)
Toxicant-associated steatohepatitis in vinyl chloride workers.
Hepatology. 2010, 51(2), 474-81
»Abstract

Dechêne A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. (2010)
Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation.
Hepatology 2010, 52(3), 1008-16
»Abstract

Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010)
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Br J Cancer 2010, 102(3), 577-582
»Abstract

Estep JM, Birerdinc A, Younossi Z. (2010)
Non-invasive diagnostic tests for non-alcoholic fatty liver disease.
Curr Mol Med. 2010, 10(2), 166-172
»Abstract

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. (2010)
Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis.
Hepatology 2010, 51(1), 92-102
»Abstract

Linder S, Olofsson MH, Herrmann R, Ulukaya E. (2010)
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Expert Rev Mol Diagn. 2010, 10(3), 353-9
»Abstract

Paschos KA, Charsou C, Constantinidis TC, Anagnostoulis S, Lambropoulou M, Papachristou F, Simopoulos K, Chatzaki E. (2010)
Corticotropin-releasing hormone receptors mediate opposing effects in cholestasis-induced liver cell apoptosis.
Endocrinology. 2010, 151(4), 1704-12
»Abstract

Samuel D, Ichai P. (2010)
Prognosis indicator in acute liver failure: Is there a place for cell death markers?
J Hepatol. 2010, 53(4), 593-5
»Abstract

Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T, Sugawara S, Kawashima A, Okita M, Tsukamoto I. (2010)
Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD).
J Nutr Sci Vitaminol (Tokyo). 2010, 56(5), 271-8.
»Abstract

Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K. (2010)
Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
J Clin Gastroenterol. 2010, 44(6), 440-7
»Abstract

Ulukaya S, Ulukaya E, Alper I, Yilmaztepe-Oral A, Kilic M. (2010)
Soluble cytokeratin 18 biomarkers may provide information on the type of cell death during early ischemia and reperfusion periods of liver transplantation.
Clin Transplant. 2010, 24(6), 848-54
»Abstract

Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. (2010)
Serum M30 levels are associated with survival in advanced gastric carcinoma patients.
Int Immunopharmacol. 2010, 10(7), 719-22
»Abstract

Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. (2010)
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis.
Obes Surg. 2010, 21(4), 431-9
»Abstract


Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, Hamilton G (2009)
Circulating Cytokeratin 18 Fragment M65-A Potential Marker of Malignancy in Colorectal Cancer Patients.
J Gastrointest Surg. 2009, 13(11), 43983
»Abstract

Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G. (2009)
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Eur J Surg Oncol. 2009, 35(11), 1164-8
»Abstract

Bantel H, Schulze-Osthoff K. (2009)
Cell death in sepsis: a matter of how, when, and where.
Crit Care. 2009, 13(4), 173
»Abstract

Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. (2009)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Cancer Gene Ther. 2009, 16(7), 567-72
»Abstract

Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand MA (2009)
Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction.
Crit Care. 2009, 13(3), R93
»Abstract

Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. (2009)
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Am J Pathol. 2009, 175(2), 808-16
»Abstract

Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. (2009)
Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae.
Digestion. 2009, 80(4), 235-40
»Abstract

Koelink PJ, Lamers CB, Hommes DW, Verspaget HW (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer 2009, 9, 88
»Abstract

Koelink PJ, Mieremet-Ooms MA, Corver WE, Wolanin K, Hommes DW, Lamers CB, Verspaget HW. (2009)
5-Aminosalicylic Acid Interferes in the Cell Cycle of Colorectal Cancer Cells and Induces Cell Death Modes
Inflamm Bowel Dis 2009, 16(3), 379-89
»Abstract

Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW. (2009)
Clinical significance of stromal apoptosis in colorectal cancer.
Br J Cancer 2009, 101(5), 765-73
»Abstract

Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer. 2009, , 23;9:88
»Abstract

Linder S, Alaiya A. (2009)
Serum efficacy biomarkers for oncology.
Biomark Med 2009, 3(1), 47-54
»Abstract

Olofsson M H, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S (2009)
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Cancer Biomark. 2009, 5(3), 117-25
»Abstract

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. (2009)
Elevated Serum Levels of M30 and M65 in Patients with Locally Advanced Head and Neck Tumors.
Int Immunopharmacol. 2009, 9(5), 645-8
»Abstract

Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009)
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
Br J Cancer 2009, 101(3), 410-7
»Abstract

Yilmaz Y, (2009)
Systematic review: caspase-cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease
Aliment Pharmacol Ther 2009, 30(11-12), 1103-9
»Abstract


Carpinelli P, Moll J. (2008)
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers
Expert Opinion On Therapeutic Targets 2008, 12 (1), 69-80
»Abstract

Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2008)
Biomarker method validation in anticancer drug development.
Br J Pharmacol 2008, 153(4), 646-656
»Abstract

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C. (2008)
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Mol Cancer Ther. 2008, 7(3), 455-63
»Abstract

de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA. (2008)
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
Neoplasia 2008, 10 (10), 1041-8
»Abstract

Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. (2008)
Optimisation of circulating biomarkers of cell death for routine clinical use.
Ann Oncol. 2008, 19(5), 990-5
»Abstract

Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P. (2008)
Apoptosis and necrosis: detection, discrimination and phagocytosis.
Methods. 2008, 44 (3), 205-221
»Abstract

Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K. (2008)
Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
Clin Cancer Res. 2008, 14(22), 7304-7310
»Abstract

Volkmann X, Anstaett, M., Hadem, J., Stiefel, P., Bahr, M J., Frank, L., Manns, M P., Schulze-Osthoff, K., Bantel, H. (2008)
Caspase activation is associated with spontaneous recovery from acute liver failure.
Hepatology 2008, 22237, 1624-1633
»Abstract

Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. (2008)
Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease.
J Pediatr Gastroenterol Nutr 2008, 47(4), 481-5
»Abstract

Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. (2008)
A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH).
Obes Surg 2008, ,
»Abstract


Bechmann L P, Guido Marquitan, Christoph Jochum, Fuat Saner, Guido Gerken, Ali Canbay (2007) (2007)
Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute‑on‑chronic liver failure
Liver International 2007, 2007, 1478-3231
»Abstract

Cummings J, Ranson M, Butt F, Moore D, Dive C (2007)
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cancer Chemother Pharmacol 2007, , 921-4
»Abstract

Klenk M, Nakata M, Podbielski A, Skupin B, Schroten H, Kreikemeyer B. (2007)
Streptococcus pyogenes serotype-dependent and independent changes in infected HEp-2 epithelial cells
ISME J. 2007, 1:8, 678-92
»Abstract

Linder S, (2007)
Cytokeratin Markers Come of Age
Tumour Biol 2007, 28(4), 189-195
»Abstract

Olofsson M H, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. (2007)
Cytokeratin 18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy
Clin Cancer Res 2007, 13(11), 3198-3206 
»Abstract

Voorzanger-Rousselot N, Garnero P (2007)
Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses
Cancer Treat Rev. 2007, 33 (3), 230-283
»Abstract

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. (2007)
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.
World J Gastroenterol 2007, 13(6), 837-44
»Abstract


Cummings J, Ward TH, Ranson M, Dive C. (2004)
Apoptosis pathway-targeted drugs - from the bench to the clinic.
Biochim Biophys Acta 2004, 1705(1), 53-66
»Abstract

Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C.. (2006)
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
Br J Cancer 2006, 95, 42-48
»Abstract

Erdal H, Berndtsson, M., Castro, J., Brunk, U., Shoshan, M.C. and Linder, S (2005)
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis.
Proc. Natl. Acad. Sci. USA 2005, 102, 192-197
»Abstract

Kramer G, Erdal, H., Mertens, H., Nap, M., Mauermann, J., Steiner, G., Marberger, M., Bivén, K., Shoshan, M.C. and Linder, S. (2004)
Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18.
Cancer Research 2004, 64, 1751-1756
»Abstract

Kramer G, Schwartz, S., Hägg, M., Mandic Havelka, A. and Linder, S (2006)
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Br J Cancer 2006, 94(11), 1592-8
»Abstract

Shoshan M, Mandic Havelka A, Neumann F and Linder S (2006)
Sense and sensibility: the use of cell death biomarker assays in high-throughput anticancer drug screening and monitoring treatment responses.
Expert Opin. Drug Discov 2006, Vol. 1 No. 6, 585-594

Ueno T, Toi, M. and Linder, S (2005)
Detection of epithelial cell death in the body by cytokeatin 18 measurement.
Biomed&Pharmacotherapy 2005, , 359-362
»Abstract